1. Home
  2. APRE vs AQMS Comparison

APRE vs AQMS Comparison

Compare APRE & AQMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Aprea Therapeutics Inc.

APRE

Aprea Therapeutics Inc.

HOLD

Current Price

$0.23

Market Cap

5.7M

Sector

Health Care

ML Signal

HOLD

Logo Aqua Metals Inc.

AQMS

Aqua Metals Inc.

HOLD

Current Price

$0.66

Market Cap

5.2M

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
APRE
AQMS
Founded
2006
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Metal Fabrications
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
5.7M
5.2M
IPO Year
2019
2015

Fundamental Metrics

Financial Performance
Metric
APRE
AQMS
Price
$0.23
$0.66
Analyst Decision
Strong Buy
Buy
Analyst Count
4
2
Target Price
$3.30
★ $5.00
AVG Volume (30 Days)
★ 133.5K
29.6K
Earning Date
11-04-2026
11-16-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 21.22
N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $2,100,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$600.00
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.39
$0.95
52 Week High
$1.49
$8.31

Technical Indicators

Market Signals
Indicator
APRE
AQMS
Relative Strength Index (RSI) 26.17 22.41
Support Level N/A N/A
Resistance Level $0.81 $2.98
Average True Range (ATR) 0.06 0.20
MACD -0.01 -0.03
Stochastic Oscillator 8.91 0.00

Price Performance

Historical Comparison
APRE
AQMS

About APRE Aprea Therapeutics Inc.

Aprea Therapeutics Inc is a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. It develops small molecule inhibitors designed to exploit genetic mutations in cancer to widen the therapeutic window and is intended to make treatments more effective at destroying cancer cells while sparing healthy tissue. The company's pipeline of clinical and preclinical programs includes APR-1051, a WEE1 inhibitor; ATRN-119 (Mosipasertib), an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related, or ATR; and an early-stage program, APR-1602. These candidates are being developed for broad applications in cancer treatment.

About AQMS Aqua Metals Inc.

Aqua Metals Inc is developing and seeking to commercialize proprietary recycling and refining technologies for the recovery of critical minerals and metals. Its patented and patent-pending AquaRefining process is an electro-hydrometallurgical method designed to recover high-purity materials from battery and other metal-bearing feedstocks using a closed-loop system powered by electricity. Its idea is to reduce CAPEX and OPEX costs, reduce emissions, hazardous waste, and reliance on conventional smelting and chemical-intensive refining processes. It has one operating segment: sustainable metals recycling. It focused on the development and commercialization of AquaRefining technology for the clean and efficient recovery of valuable metals from lead-acid and lithium-ion batteries.

Share on Social Networks: